Related references
Note: Only part of the references are listed.Bispecific antibodies
Ulrich Brinkmann et al.
SCIENCE (2021)
A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
Nadine Aschmoneit et al.
SCIENTIFIC REPORTS (2021)
Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules
Oliver Seifert et al.
MABS (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes
Roman Fischer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
IgE Antibodies: From Structure to Function and Clinical Translation
Brian J. Sutton et al.
ANTIBODIES (2019)
EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies
Heather A. Cooke et al.
MABS (2018)
A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture
Chunlei Wang et al.
MABS (2018)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
Lisa C. Schmitt et al.
MABS (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Meike Hutt et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Julian Andreev et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Engineering bispecific antibodies with defined chain pairing
Simon Krah et al.
NEW BIOTECHNOLOGY (2017)
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
Anke Steinmetz et al.
MABS (2016)
Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63
Bart E. C. G. de Goeij et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
Ji-Hee Ha et al.
FRONTIERS IN IMMUNOLOGY (2016)
Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies
Xiufeng Wu et al.
MABS (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties
Oliver Seifert et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar
Zhongyu Zhu et al.
MABS (2014)
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Steven M. Lewis et al.
NATURE BIOTECHNOLOGY (2014)
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design
Enrico L. DiGiammarino et al.
MABS (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A current understanding of FccRI-dependent mast cell activation
Juan Rivera et al.
CURRENT ALLERGY AND ASTHMA REPORTS (2008)
A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo
Tobias Martens et al.
CLINICAL CANCER RESEARCH (2006)
The crystal structure of IgE Fc reveals an asymmetrically bent conformation
T Wan et al.
NATURE IMMUNOLOGY (2002)
Structural insights into the interactions between human IgE and its high affinity receptor FcεRI
BA Wurzburg et al.
MOLECULAR IMMUNOLOGY (2002)
The structure of the IgE Cε2 domain and its role in stabilizing the complex with its high-affinity receptor FcεRlα
JM McDonnell et al.
NATURE STRUCTURAL BIOLOGY (2001)
Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα
SC Garman et al.
NATURE (2000)
Share Paper
